In Vivo Cell Depletion: Antibody Targets, Fc Mechanisms and Dosing

A depletion experiment is only as good as the depletion you can prove. Injecting a functional-grade antibody and assuming the population is gone is the most common failure mode in in vivo immunology. The marker sets which cells are targeted, the Fc region decides whether they are lysed, eaten or merely coated, and the tissue decides how complete the loss really is. This atlas maps ten validated depleting targets onto the populations they remove and onto the three effector mechanisms that do the work.

Which marker removes which population

The T-cell targets divide by breadth. Anti-CD3 (145-2C11) hits every T cell; anti-CD4 (GK1.5) removes helper T cells but also regulatory T cells and a slice of the innate lymphoid compartment; anti-CD8 leaves helpers intact. Anti-CD25 is usually described as a Treg reagent, but CD25 is an activation marker — recently primed effectors go with them. Anti-CD90/Thy-1 (HK2.1) is the broadest option and reaches tissue-resident T cells that anti-CD3 often spares.

On the B-cell side the two options are not interchangeable. Anti-CD19 is tightly restricted to the B lineage. Anti-CD45R/B220 (RA3-6B2) is broader: B220 is also carried by plasmacytoid dendritic cells and subsets of activated T and NK cells. Neither reaches long-lived plasma cells, which have downregulated both markers — which is why serum IgG can stay flat for weeks after an apparently complete B-cell depletion.

For innate targets, strain and selectivity both matter. Anti-NK1.1 (PK136) depletes NK and NKT cells, but only in NK1.1-expressing strains such as C57BL/6, not BALB/c. Anti-Ly6G (1A8) is the neutrophil-selective choice, whereas anti-Gr-1 (RB6-8C5) recognises Ly6G and Ly6C together and removes neutrophils, inflammatory monocytes and monocytic MDSC in one dose. Attributing a Gr-1 phenotype to neutrophils alone is a recurring error.

How the antibody actually kills: ADCC, ADCP and CDC

Binding does very little on its own. Once the Fab arm has engaged antigen on the target cell, the Fc tail recruits an effector. In antibody-dependent cellular cytotoxicity, clustered Fc regions crosslink FcγRIII (CD16) on an NK cell and trigger degranulation: perforin oligomerises in the target membrane and granzyme B enters to initiate apoptosis. Because both proteins are released, perforin and granzyme B in serum or tissue lysate record that this arm actually fired.

Antibody-dependent cellular phagocytosis is the numerically dominant route in a mouse, and it is anatomically concentrated. Splenic red-pulp and marginal-zone macrophages and hepatic Kupffer cells carry high levels of activating FcγR and strip or engulf opsonised cells as they pass through. Most depletion therefore happens in liver and spleen rather than in the circulation, which is why clodronate pre-treatment or splenectomy can blunt an otherwise reliable depleting antibody.

Complement-dependent cytotoxicity begins when C1q docks onto a hexameric array of surface-bound IgG, driving C3 cleavage and assembly of the C5b-9 membrane attack complex. Two points are worth separating: the lytic MAC route is weak for most rat- and hamster-derived clones in mouse serum, but C3b deposited in the same reaction is a potent opsonin feeding straight back into phagocytosis via CR3. Complement mostly amplifies ADCP rather than lysing anything.

Isotype decides the outcome, not affinity

The same variable region on a different constant region gives a different experiment. Mouse IgG2a (IgG2c in C57BL/6) has the most favourable ratio of activating to inhibitory FcγR engagement, binds FcγRIV strongly, and is the best depleter. IgG1 engages FcγRIII and the inhibitory FcγRIIB and depletes poorly — useful if you want blockade without deletion. Most commercial depleting clones are rat IgG2b or IgG2a, which engage mouse FcγRIV efficiently.

This is why blocking and depleting reagents cannot be swapped casually. A rat IgG1 anti-CD25 partly neutralises IL-2 signalling and only partly deletes Tregs, while an IgG2a-switched version of the same clone deletes them efficiently — two very different readings of one knockdown. Hamster IgG anti-CD3 (145-2C11) differs again: much of its effect is TCR modulation and activation-induced death, with a first-dose cytokine-release response that is itself a biological effect.

Dosing, timing and verification

A workable default is a loading dose of 200–500 µg intraperitoneally, repeated after 48–72 hours, then 100–250 µg every three to four days. Depletion is usually maximal 24–72 hours after the first dose. Rat IgG has a half-life of roughly a week in mice, but anti-rat responses develop after about two weeks and silently restore the population, so long studies need periodic re-verification rather than a single end-point check.

Verify with a non-competing clone. After GK1.5 the CD4 epitope is both masked by residual circulating antibody and downmodulated on surviving cells, so re-staining with the same clone reports depletion that has not occurred; use a non-competing anti-CD4 or gate CD3⁺CD8⁻. Block Fc receptors with anti-CD16/CD32 (2.4G2) before staining, and check spleen, lymph node and the target tissue — blood clears first and always overstates efficiency.

Common pitfalls and the controls that catch them

Incomplete depletion is the norm in some compartments. Bone marrow, gut intraepithelial lymphocytes, liver, central nervous system and the core of a solid tumour are all comparatively protected, because effector macrophages are scarce or antibody penetration is poor. Antigenic modulation compounds it: trogocytosis by FcγR-bearing cells shaves the target antigen off without killing the cell, so a functionally intact population reappears marker-negative and is scored as depleted.

Controls should match on species, isotype, formulation and schedule — not just on the word "control". Endotoxin is the usual confounder: trace LPS in either preparation activates the same myeloid cells you are studying, so low-endotoxin, azide-free material is needed on both arms. Depletion is also not a clean subtraction: the resulting lymphopenia drives homeostatic proliferation and a more effector-like phenotype in whatever survives.

Key targets and matching reagents

Studying depletion in vivo

Every target on this map is available as a low-endotoxin, azide-free functional-grade antibody, and the experiments fall into three groups.

1. Depleting the lymphocyte compartment

Anti-CD3 (145-2C11) for pan-T loss, anti-CD4 (GK1.5) and anti-CD8 to separate helper from cytotoxic contributions, anti-CD25 for regulatory T cells, and anti-CD90/Thy-1 (HK2.1) when tissue-resident T cells must go too. For B cells, choose anti-CD19 for lineage precision or anti-CD45R/B220 (RA3-6B2) for breadth, and pair the two if you need to attribute a phenotype to a B220⁺ non-B population.

2. Depleting innate and myeloid populations

Anti-NK1.1 (PK136) removes NK and NKT cells in C57BL/6 backgrounds. For granulocytes, run anti-Ly6G (1A8) and anti-Gr-1 (RB6-8C5) side by side: a phenotype present with Gr-1 but absent with Ly6G points at monocytes or MDSC rather than neutrophils. Anti-CD16/CD32 (2.4G2) blocks FcγRII/III, both as a staining block and as a way to test how much of a depleting effect is Fc-dependent.

3. Confirming the mechanism, not just the loss

Depletion experiments are more persuasive when the effector arm is measured. Perforin and granzyme B ELISAs report the cytotoxic ADCC arm; C1q and C3 ELISAs track complement consumption and test whether a phenotype survives complement depletion. With flow verification in tissue, these turn a binary "cells gone" claim into a mechanism. The full In Vivo range is low-endotoxin and azide-free.

Featured products for this pathway

Frequently asked questions

For research use only. Not for use in diagnostic or therapeutic procedures.